Literature DB >> 12563294

Hide, shield and strike back: how HIV-infected cells avoid immune eradication.

B Matija Peterlin1, Didier Trono.   

Abstract

Viruses that induce chronic infections can evade immune responses. HIV is a prototype of this class of pathogen. Not only does it mutate rapidly and make its surface components difficult to access by neutralizing antibodies, but it also creates cellular hideouts, establishes proviral latency, removes cell-surface receptors and destroys immune effectors to escape eradication. A better understanding of these strategies might lead to new approaches in the fight against AIDS.

Entities:  

Mesh:

Year:  2003        PMID: 12563294     DOI: 10.1038/nri998

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  46 in total

1.  Neutron reflectometry study of the conformation of HIV Nef bound to lipid membranes.

Authors:  Michael S Kent; Jaclyn K Murton; Darryl Y Sasaki; Sushil Satija; Bulent Akgun; Hirsh Nanda; Joseph E Curtis; Jaroslaw Majewski; Christopher R Morgan; John R Engen
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

2.  HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors:  Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

3.  HIV dynamics with multiple infections of target cells.

Authors:  Narendra M Dixit; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

4.  Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.

Authors:  Ann Florence B Victoriano; Kaori Asamitsu; Yurina Hibi; Kenichi Imai; Nina G Barzaga; Takashi Okamoto
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein.

Authors:  Stéphane Betzi; Audrey Restouin; Sandrine Opi; Stefan T Arold; Isabelle Parrot; Françoise Guerlesquin; Xavier Morelli; Yves Collette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

6.  RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.

Authors:  Kelly M Marno; Eithne O'Sullivan; Christopher E Jones; Julieta Díaz-Delfín; Claire Pardieu; Richard D Sloan; Áine McKnight
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

7.  Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha.

Authors:  Biswanath Majumder; Narasimhan J Venkatachari; Elizabeth A Schafer; Michelle L Janket; Velpandi Ayyavoo
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knock-out mice.

Authors:  Katelyn M Atkins; Laurel Thomas; Robert T Youker; Melanie J Harriff; Franco Pissani; Huihong You; Gary Thomas
Journal:  J Biol Chem       Date:  2008-02-22       Impact factor: 5.157

Review 9.  HIV-1 Nef in macrophage-mediated disease pathogenesis.

Authors:  Susanna L Lamers; Gary B Fogel; Elyse J Singer; Marco Salemi; David J Nolan; Leanne C Huysentruyt; Michael S McGrath
Journal:  Int Rev Immunol       Date:  2012-12       Impact factor: 5.311

10.  HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.

Authors:  Weifeng Xu; Paul A Santini; John S Sullivan; Bing He; Meimei Shan; Susan C Ball; Wayne B Dyer; Thomas J Ketas; Amy Chadburn; Leona Cohen-Gould; Daniel M Knowles; April Chiu; Rogier W Sanders; Kang Chen; Andrea Cerutti
Journal:  Nat Immunol       Date:  2009-08-02       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.